6avg - Revision history

OCA at 07:10, 28 March 2018

OCA — Wed, 28 Mar 2018 07:10:23 GMT

←Older revision		Revision as of 07:10, 28 March 2018
Line 3:		Line 3:
	<StructureSection load='6avg' size='340' side='right' caption='[[6avg]], [[Resolution\|resolution]] 2.60Å' scene=''>		<StructureSection load='6avg' size='340' side='right' caption='[[6avg]], [[Resolution\|resolution]] 2.60Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[6avg]] is a 10 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6AVG OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6AVG FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[6avg]] is a 10 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6AVG OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6AVG FirstGlance]. <br>
	</td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[6at5\|6at5]], [[6at6\|6at6]], [[6avf\|6avf]]</td></tr>		</td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[6at5\|6at5]], [[6at6\|6at6]], [[6avf\|6avf]]</td></tr>
		+	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">B2M, CDABP0092, HDCMA22P ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN]), TRAV4 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN]), TRBV9 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN]), HLA-B, HLAB ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6avg FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6avg OCA], [http://pdbe.org/6avg PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6avg RCSB], [http://www.ebi.ac.uk/pdbsum/6avg PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6avg ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6avg FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6avg OCA], [http://pdbe.org/6avg PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6avg RCSB], [http://www.ebi.ac.uk/pdbsum/6avg PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6avg ProSAT]</span></td></tr>
	</table>		</table>
Line 11:		Line 12:
	== Function ==		== Function ==
	[[http://www.uniprot.org/uniprot/1B07_HUMAN 1B07_HUMAN]] Involved in the presentation of foreign antigens to the immune system. [[http://www.uniprot.org/uniprot/B2MG_HUMAN B2MG_HUMAN]] Component of the class I major histocompatibility complex (MHC). Involved in the presentation of peptide antigens to the immune system.		[[http://www.uniprot.org/uniprot/1B07_HUMAN 1B07_HUMAN]] Involved in the presentation of foreign antigens to the immune system. [[http://www.uniprot.org/uniprot/B2MG_HUMAN B2MG_HUMAN]] Component of the class I major histocompatibility complex (MHC). Involved in the presentation of peptide antigens to the immune system.
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Human leukocyte antigen (HLA)-I molecules generally bind short peptides (8-10 amino acids), although extended HLA-I restricted peptides (>10 amino acids) can be presented to T cells. However, the function of such extended HLA-I epitopes in tumour immunity, and how they would be recognised by T-cell receptors (TCR) remains unclear. Here we show that the structures of two distinct TCRs (TRAV4(+)TRAJ21(+)-TRBV28(+)TRBJ2-3(+) and TRAV4 (+) TRAJ8(+)-TRBV9(+)TRBJ2-1(+)), originating from a polyclonal T-cell repertoire, bind to HLA-B07:02, presenting a 13-amino-acid-long tumour-associated peptide, NY-ESO-160-72. Comparison of the structures reveals that the two TCRs differentially binds NY-ESO-160-72-HLA-B07:02 complex, and induces differing extent of conformational change of the NY-ESO-160-72 epitope. Accordingly, polyclonal TCR usage towards an extended HLA-I restricted tumour epitope translates to differing TCR recognition modes, whereby extensive flexibility at the TCR-pHLA-I interface engenders recognition.
		+
		+	Divergent T-cell receptor recognition modes of a HLA-I restricted extended tumour-associated peptide.,Chan KF, Gully BS, Gras S, Beringer DX, Kjer-Nielsen L, Cebon J, McCluskey J, Chen W, Rossjohn J Nat Commun. 2018 Mar 12;9(1):1026. doi: 10.1038/s41467-018-03321-w. PMID:29531227<ref>PMID:29531227</ref>
		+
		+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
		+	</div>
		+	<div class="pdbe-citations 6avg" style="background-color:#fffaf0;"></div>
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Human]]
	[[Category: Gras, S]]		[[Category: Gras, S]]
	[[Category: Gully, B S]]		[[Category: Gully, B S]]

OCA at 06:30, 28 February 2018

OCA — Wed, 28 Feb 2018 06:30:44 GMT

←Older revision		Revision as of 06:30, 28 February 2018
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 6avg is ~~ON HOLD~~ ~~until Paper Publication~~	+	==Crystal structure of the KFJ37 TCR-NY-ESO-1-HLA-B*07:02 complex==
-		+	<StructureSection load='6avg' size='340' side='right' caption='[[6avg]], [[Resolution\|resolution]] 2.60Å' scene=''>
-	~~Authors~~:	+	== Structural highlights ==
-		+	<table><tr><td colspan='2'>[[6avg]] is a 10 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6AVG OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6AVG FirstGlance]. <br>
-	~~Description~~:	+	</td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[6at5\|6at5]], [[6at6\|6at6]], [[6avf\|6avf]]</td></tr>
-	[[Category: ~~Unreleased Structures~~]]	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6avg FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6avg OCA], [http://pdbe.org/6avg PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6avg RCSB], [http://www.ebi.ac.uk/pdbsum/6avg PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6avg ProSAT]</span></td></tr>
		+	</table>
		+	== Disease ==
		+	[[http://www.uniprot.org/uniprot/B2MG_HUMAN B2MG_HUMAN]] Defects in B2M are the cause of hypercatabolic hypoproteinemia (HYCATHYP) [MIM:[http://omim.org/entry/241600 241600]]. Affected individuals show marked reduction in serum concentrations of immunoglobulin and albumin, probably due to rapid degradation.<ref>PMID:16549777</ref> Note=Beta-2-microglobulin may adopt the fibrillar configuration of amyloid in certain pathologic states. The capacity to assemble into amyloid fibrils is concentration dependent. Persistently high beta(2)-microglobulin serum levels lead to amyloidosis in patients on long-term hemodialysis.<ref>PMID:3532124</ref> <ref>PMID:1336137</ref> <ref>PMID:7554280</ref> <ref>PMID:4586824</ref> <ref>PMID:8084451</ref> <ref>PMID:12119416</ref> <ref>PMID:12796775</ref> <ref>PMID:16901902</ref> <ref>PMID:16491088</ref> <ref>PMID:17646174</ref> <ref>PMID:18835253</ref> <ref>PMID:18395224</ref> <ref>PMID:19284997</ref>
		+	== Function ==
		+	[[http://www.uniprot.org/uniprot/1B07_HUMAN 1B07_HUMAN]] Involved in the presentation of foreign antigens to the immune system. [[http://www.uniprot.org/uniprot/B2MG_HUMAN B2MG_HUMAN]] Component of the class I major histocompatibility complex (MHC). Involved in the presentation of peptide antigens to the immune system.
		+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Gras, S]]
		+	[[Category: Gully, B S]]
		+	[[Category: Rossjohn, J]]
		+	[[Category: Human leukocyte antigen]]
		+	[[Category: Immune system]]
		+	[[Category: Immunoglobulin]]
		+	[[Category: Major histocompatibility complex]]
		+	[[Category: T cell receptor]]

OCA at 06:19, 15 November 2017

OCA — Wed, 15 Nov 2017 06:19:02 GMT

←Older revision		Revision as of 06:19, 15 November 2017
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 6avg is ON HOLD	+	The entry 6avg is ON HOLD until Paper Publication

	Authors:		Authors:

OCA: Protected "6avg" [edit=sysop:move=sysop]

OCA — Wed, 27 Sep 2017 16:50:17 GMT

Protected "6avg" [edit=sysop:move=sysop]

←Older revision

Revision as of 16:50, 27 September 2017

OCA: New page: '''Unreleased structure''' The entry 6avg is ON HOLD Authors: Description: Category: Unreleased Structures

OCA — Wed, 27 Sep 2017 16:50:16 GMT

New page: '''Unreleased structure''' The entry 6avg is ON HOLD Authors: Description: Category: Unreleased Structures

New page

'''Unreleased structure'''

The entry 6avg is ON HOLD

Authors:

Description:
[[Category: Unreleased Structures]]